Literature DB >> 26449139

Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy.

Paolo Ferrazzi1, Paolo Spirito2, Attilio Iacovoni3, Alice Calabrese3, Katrin Migliorati4, Caterina Simon5, Samuele Pentiricci5, Daniele Poggio4, Massimiliano Grillo4, Pietro Amigoni4, Maria Iascone6, Andrea Mortara4, Barry J Maron7, Michele Senni3, Paolo Bruzzi8.   

Abstract

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) and mild septal hypertrophy, mitral valve (MV) abnormalities may play an important role in MV displacement into the left ventricular (LV) outflow tract. Therefore, isolated myectomy may not relieve outflow obstruction and symptoms, and MV replacement is often the surgical alternative.
OBJECTIVES: This study sought to assess the clinical and hemodynamic results of cutting thickened secondary MV chordae combined with a shallow septal muscular resection in severely symptomatic patients with obstructive HCM and mild septal hypertrophy.
METHODS: Clinical features were compared before surgery and at most recent clinical evaluation in 39 consecutive patients with obstructive HCM.
RESULTS: Over a 23 ± 2 months follow-up, New York Heart Association functional class decreased from 2.9 ± 0.5 pre-operatively to 1.1 ± 1.1 post-operatively (p < 0.001), with no patient in class III at most recent evaluation. The resting outflow gradient decreased from 82 ± 43 mm Hg to 9 ± 5 mm Hg (p < 0.001) and septal thickness decreased from 17 ± 1 mm to 14 ± 2 mm (p < 0.001). No patient had MV prolapse or flail and 1 had residual moderate-to-severe MV regurgitation at most recent evaluation. MV geometry before and after surgery was compared with that of 25 consecutive patients with similar clinical profile and septal thickness that underwent isolated myectomy. After adjustment for differences in pre-operative values between the groups, the post-operative anterior MV leaflet-annulus ratio was 17% greater and tenting area 24% smaller in patients with chordal cutting, indicating that MV apparatus had moved to a more normal posterior position within the LV cavity, preventing MV systolic displacement into the outflow tract and outflow obstruction.
CONCLUSIONS: This procedure relieves heart failure symptoms, abolishes LV outflow gradient, and avoids MV replacement in patients with obstructive HCM and mild septal thickness.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  heart failure; septal myectomy; ventricular septum

Mesh:

Year:  2015        PMID: 26449139     DOI: 10.1016/j.jacc.2015.07.069

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

Review 1.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

2.  Alcohol septal ablation: in which patients and why?

Authors:  Paolo Spirito; Jessica Rossi; Barry J Maron
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 3.  Transaortic mitral valve secondary chordal cutting in patients with obstructive hypertrophic cardiomyopathy and mild septal hypertrophy.

Authors:  Irene Binaco; Paolo Spirito; Daniele Poggio; Valter Casati; Massimiliano Grillo; Paolo Ferrazzi
Journal:  Ann Cardiothorac Surg       Date:  2017-07

4.  Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience.

Authors:  Hassan Rastegar; Griffin Boll; Ethan J Rowin; Noreen Dolan; Catherine Carroll; James E Udelson; Wendy Wang; Philip Carpino; Barry J Maron; Martin S Maron; Frederick Y Chen
Journal:  Ann Cardiothorac Surg       Date:  2017-07

5.  Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy.

Authors:  Franco Cecchi; Maria Iascone; Niccolò Maurizi; Laura Pezzoli; Irene Binaco; Elena Biagini; Maria Laura Fibbi; Iacopo Olivotto; Federico Pieruzzi; Ana Fruntelata; Lucian Dorobantu; Claudio Rapezzi; Paolo Ferrazzi
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

6.  Septal Thickness Does Not Impact Outcome After Hypertrophic Obstructive Cardiomyopathy Surgery (Septal Myectomy and Subvalvular Mitral Apparatus Remodeling): A 15-Years of Experience.

Authors:  Giuseppe M Raffa; Eluisa La Franca; Carlo Lachina; Andrea Palmeri; Mariusz Kowalewski; Steven Lebowitz; Alessandro Ricasoli; Matteo Greco; Sergio Sciacca; Marco Turrisi; Marco Morsolini; Vincenzo Stringi; Gabriella Mattiucci; Michele Pilato
Journal:  Front Cardiovasc Med       Date:  2022-06-15

7.  Minimally invasive trans-mitral septal myectomy for diffuse-type hypertrophic obstructive cardiomyopathy.

Authors:  Taichi Sakaguchi; Toshinori Totsugawa; Kentaro Tamura; Arudo Hiraoka; Genta Chikazawa; Hidenori Yoshitaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-16

Review 8.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 9.  Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Victor Arévalos; Juan José Rodríguez-Arias; Salvatore Brugaletta; Antonio Micari; Francesco Costa; Xavier Freixa; Mónica Masotti; Manel Sabaté; Ander Regueiro
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

10.  Targeting Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy Candidates for Surgical Myectomy: Added Value of Three-Dimensional Intracoronary Myocardial Contrast Echocardiography.

Authors:  Giovanni La Canna; Iside Scarfò; Irina Arendar; Antonio Colombo; Lucia Torracca; Davide Margonato; Matteo Montorfano; Ottavio Alfieri
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.